March 2018. The BPA was activated in November 2017. The primary outcome was UCx performed/1,000 patient-days.
Results. During the 4-month intervention period, the BPA was activated 120 times. The UCx order was replaced by a UA with reflex to culture in 47% (56/120) of cases, while removal of the UCx alone was seen in 6% (7/120) of cases. The remainder of cases did not remove the original order with reasons including urine sample obtained by straight catheterization, urine culture added to prior urinalysis, a critically ill patient with encephalopathy ( Figure 2 ). During the intervention period, there was a statistically significant decrease in both the number of standalone UCx performed from 41.2/1,000 patient-days to 30.1/1,000 patient-days (P = 0.008) and the total number of UCx performed 58.7/1,000 patient-days to 53.0/1,000 patient-days (P = 0.02) (Figure 3) .
Conclusion. Implementation of a BPA to prevent the use of standalone UCx in favor of a UA with reflex culture reduced the total number of UCx performed. Background. The Christiana Care Antimicrobial Stewardship Program developed a pilot initiative for tracking and monitoring antibiotic utilization across the health system. This initiative aligns with the Joint Commission's elements of performance, which calls for tracking and reporting of antibiotic prescribing, as well as the Centers for Medicare and Medicaid Services recommendations for documentation of antibiotic indication, dose, and duration with each order. A customized indication list in the order entry field was created for cefepime, ceftriaxone, levofloxacin, and ciprofloxacin orders.
Evaluation of a Pilot Initiative for Tracking and Monitoring Indications
Methods. A retrospective chart review of antibiotic indications was completed. A maximum of 50 orders per each antibiotic from December 31, 2017 to January 6, 2018 were randomly selected to be evaluated. The primary endpoint of our study was the percent of cases in which the indication was selected according to the true indication per chart review. Secondary endpoints included the percent of cases in which "other indication" was selected where an available indication was appropriate, percent of cases in which the appropriate dose and frequency were prescribed, and percent of cases in which the duration of therapy was appropriate for urinary tract infections (UTIs).
Results. A total of 540 orders were profiled between December 31, 2017 and January 6, 2018, of which 182 were reviewed. In regards to the accuracy of selected indication, 94% of cefepime, 88% of ceftriaxone, 78% of ciprofloxacin, and 89% of levofloxacin orders were considered appropriate. Dosing was most appropriate among ciprofloxacin orders (100%), followed by ceftriaxone (96%), cefepime (94%), and levofloxacin (74%). Frequency was most appropriate among ceftriaxone orders (98%), followed by ciprofloxacin (87%), levofloxacin (78%), and cefepime (74%). Duration of therapy was appropriate in greater than 90% of UTI orders.
Conclusion. The pilot initiative for tracking and monitoring of antibiotic indications has allowed for enhanced transparency between providers regarding antimicrobial use. Further evaluation may provide greater understanding of antibiotic utilization and aid in identifying opportunities for improvements.
Disclosures. All authors: No reported disclosures. Background. In 2015, Baylor Scott and White Health (BSWH) implemented a system-wide antimicrobial stewardship program (ASP) across 22 acute care facilities. The ASP committee, led by an Infectious Diseases (ID) Physician and ID Pharmacist, includes membership of health system leadership, facility-specific ID physician and clinical pharmacy leaders, informatics, infection control, and microbiology. The committee's purpose was to facilitate local implementation of antimicrobial stewardship interventions recommended by the Centers for Disease Control and Prevention and to improve antimicrobial use at BSWH.
Successes of a System-directed and Multi-faceted Inpatient Antimicrobial Stewardship Program in a Large
Methods. The ASP created and approved antibiotic use guidelines (carbapenems, vancomycin, daptomycin, fluoroquinolones), policies, and set performance goals related to antibiotic use, which were then implemented locally at each facility. Beginning July 2016, all 22 acute care facilities went live with a clinical decision support (CDS) tool, a mobile device platform for physician access to ASP guidelines, and a requirement for antibiotic review at 48-72 hours. The CDS software also provided tracking of utilization data as days of therapy (DOT) standardized to 1,000 patient-days at risk (DAR) at the local facility and health system levels. The ASP committee tracked and reported metrics on the usage of total and targeted antibacterials, with comparisons in usage made between fiscal years (FY) 2017 and 2018. Means of total antibacterial usage and targeted antibiotics were compared between July to March of each FY using t-tests.
Results. Mean total antibacterial usage for the BSWH system was 649.6 vs. 622.6 DOT/1,000 DAR for FY17 and FY18, respectively (difference-Δ: 27.0; CI 95%: 7.9-46.1; P = 0.008). Mean targeted antibacterial usage (in DOT/1,000 DAR, FY17 vs. FY18) was 100.2 vs. 92.8 for vancomycin (Δ: 7.4; CI 95%: 5.0-9.9; P < 0.001), 30.4 vs. 20.7 for carbapenems (Δ: 9.7; CI 95%: 7.2-12.3; P < 0.001), 80.1 vs. 60.1 for fluoroquinolones (Δ: 20.0; CI 95%: 17.1-22.9; P < 0.001), and 4.6 vs. 4.4 for daptomycin (Δ: 0.2; CI 95%: -0.5-1.0; P = 0.454).
Conclusion. BSWH has made significant progress in reducing targeted and overall total antibacterial usage through the implementation of an enterprise-level antimicrobial stewardship program using a multifaceted approach.
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